<DOC>
	<DOCNO>NCT01286818</DOCNO>
	<brief_summary>The primary objective study investigate safety tolerability anti-vascular endothelial growth factor receptor-2 ( anti-VEGFR-2 ) monoclonal antibody Ramucirumab ( IMC-1121B ) combination irinotecan , levofolinate , 5-fluorouracil ( FOLFIRI ) Japanese participant advance colorectal carcinoma ( CRC ) .</brief_summary>
	<brief_title>A Study Irinotecan , Levofolinate , 5-Fluorouracil ( FOLFIRI ) Plus Ramucirumab ( IMC-1121B )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Participant Japanese Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Has histologically cytologically confirm CRC Has metastatic disease amenable potentially curative resection Has receive 2 prior systemic chemotherapy regimen set ( 1 prior regimen metastatic disease permit ) Has receive firstline combination therapy bevacizumab , oxaliplatin , fluoropyrimidine metastatic disease experience disease progression firstline therapy , disease progression within 6 month last dose firstline therapy , discontinue part firstline therapy due toxicity experience disease progression within 6 month last dose firstline therapy . Participants must receive minimum 2 dos bevacizumab part firstline regimen contain chemotherapy order enroll . Has adequate hepatic , renal , hematologic , coagulation function The participant 's urinary protein ≤1+ dipstick routine urinalysis . If urine dipstick routine analysis indicate proteinuria ≥2+ , 24hour urine must collect must demonstrate &lt; 1000 milligram ( mg ) protein 24 hour allow participation study Has receive bevacizumab within 28 day prior study registration Has receive chemotherapy within 21 day prior study registration Has receive previous systemic therapy ( combination bevacizumab , oxaliplatin , fluoropyrimidine ) firstline treatment metastatic CRC The participant experience follow firstline therapy bevacizumabcontaining regimen : arterial thrombotic/thromboembolic event ; Grade 4 hypertension ; Grade 4 proteinuria ; Grade 34 bleed event ; bowel perforation Has receive widefield ( fulldose pelvic ) radiotherapy within 28 day prior study registration Has undergone major surgery within 28 day subcutaneous venous access device placement within 7 day prior study registration Has elective plan surgery conduct trial Has history deep vein thrombosis pulmonary embolism within past 12 month Has experience arterial thrombotic event within past 12 month Participant receive therapeutic anticoagulation warfarin , lowmolecular weight heparin , similar agent Participant receive chronic therapy nonsteroidal antiinflammatory agent [ Aspirin 325 milligram per day ( mg/day ) permit ] Has significant bleed disorder significant ( Grade 3 high ) bleed event within 3 month prior registration date Has history gastrointestinal perforation and/or fistula within 6 month prior registration date Has symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia Has uncontrolled arterial hypertension despite standard medical management Has serious nonhealing wound , peptic ulcer , bone fracture within 28 day prior study registration Has acute/subacute bowel obstruction history clinically significant chronic diarrhea Has history inflammatory bowel disease Crohn 's disease require medical intervention within 12 month prior registration date The participant either peptic ulcer disease associate bleeding event know active diverticulitis Has active infection require antibiotic , antifungal , antiviral therapy Has know human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndrome ( AIDS ) relate illness Has know leptomeningeal brain metastasis uncontrolled spinal cord compression Has know history Gilbert 's Syndrome , know follow genotype : uridine diphosphate glucuronosyltransferase 1 family , polypeptide A1 ( UGT1A1 ) *6/*6 ; UGT1A1*28/*28 UGT1A1*6/*28 Has previous concurrent malignancy , except basal squamous cell skin cancer and/or situ carcinoma , solid tumor treat curatively without evidence recurrence least 3 year</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Colon Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
</DOC>